Citius Oncology shares surge 21.17% after-hours following U.S. launch of LYMPHIR, a novel CTCL immunotherapy.

Citius Oncology (CTOR) surged 21.17% in after-hours trading following the U.S. commercial launch of LYMPHIR™, an FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The drug, launched in December 2025, demonstrated a 36.2% objective response rate in pivotal trials and is now available nationwide through specialty distributors. Strategic partnerships with Cardinal Health and McKesson, along with a permanent J-code for reimbursement, were highlighted as operational enablers. The company emphasized LYMPHIR’s potential to address a $400M+ market with limited treatment options and its inclusion in NCCN guidelines. CEO Leonard Mazur underscored the therapy’s rapid efficacy and the company’s focus on execution to maximize market access. The rally reflects investor optimism over LYMPHIR’s commercialization prospects and its position as a first-in-class therapy in a high-unmet-need oncology segment.